Salvage Abdominoperineal Resection and Perineal Wound Healing in Local Recurrent or Persistent Anal Cancer

Ferenschild, Floris T. J.; Vermaas, Maarten; Hoter, Stefan O.; Verhoef, Cornelis; Eggermont, Alexander M. M.; de Wilt, Johannes H. W.
November 2005
World Journal of Surgery;Nov2005, Vol. 29 Issue 11, p1452
Academic Journal
The primary treatment for anal cancer is chemoradiation (CRT). Failures after CRT are potentially curable with an abdominoperineal resection (APR). A major problem of surgery in the anal area is poor healing of the perineal wound. Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed. Of the 24 patients with local failure, 18 patients were treated with an APR. The aim of this study was to review the results and long-term outcome after salvage APR, with special emphasis on perinea) wound healing. Mean age at diagnosis was 59 (range: 41–83) years. After a median of 16 months, only 2 patients developed a local recurrence. The 5-year overall survival was 30%. In 11 patients the perineal wound was closed primarily, in 3 patients the perineal wound was left open, and in 4 patients a vertical rectus abdominus musculocutaneous (VRAM) flap was used. Perineal wound breakdown occurred in 5 of the 14 patients (36%) not treated with primary muscle reconstruction. In all patients treated with a VRAM flap the perineal wound healed primarily. In the present study salvage AFR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%. When performing an APR a VRAM flap reconstruction should be considered to prevent disabling perineal wound complications.


Related Articles

  • Chapter 18: Ovarian Cancer Recurrence.  // Mayo Clinic Guide to Women's Cancers;2005, p327 

    This section discusses the recurrence of ovarian cancer. For too many women with ovarian cancer--especially those with later-stage disease or an aggressive type--the cancer persists or recurs after initial surgery and chemotherapy. Unfortunately, even with the most thorough surgery to remove the...

  • Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: Efficacy of a low daily dose to clinically negative regions.  // Radiation Oncology;2011, Vol. 6 Issue 1, p134 

    The article reports on a study conducted to assess the outcomes of anal cancer patients, who underwent intensity-modulated radiotherapy (IMRT) and received less than 1.80 gray (Gy) per day. It states the study was conducted using low fractional dose of IMRT to elective nodal areas of patients...

  • TN category influenced survival, relapse, colostomy failure in anal cancer.  // Hem/Onc Today;3/10/2010, Vol. 11 Issue 5, p13 

    This article focuses on a study which examined survival and relapse rates, as well as colostomy failure in patients with anal cancer.

  • Anal cancer: the case for earlier diagnosis. Edwards, A. T.; Morus, L. C.; Foster, M. E.; Griffith, G. H. // Journal of the Royal Society of Medicine;Jul1991, Vol. 84 Issue 7, p395 

    The results of treatment in 22 patients with anal carcinoma are reviewed. The overall results are disappointing with only five (28%) surviving more than 5 years. The commonest form of treatment during the study period was an abdomino-perineal excision of rectum (APER). For patients with tumours...

  • Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. AM Evens; JK Altman; BB Mittal; N Hou; A Rademaker; D Patton; L Kaminer; S Williams; S Duffey; D Variakojis; S Singhal; MS Tallman; J Mehta; JN Winter; LI Gordon // Annals of Oncology;Apr2007, Vol. 18 Issue 4, p679 

    Background: The standard approach to treatment of relapsed/refractory Hodgkin's lymphoma (HL) is high-dose chemotherapy conditioning followed by autologous hematopoietic stem-cell transplantation (aHSCT). We report the results of a prospective phase I/II clinical trial of accelerated...

  • Pre-RP Combo Could Improve PCa Outcomes. SCHIESZER, JOHN // Renal & Urology News;Jan2010, Vol. 9 Issue 1, p1 

    The article reports that radiation and chemotherapy before radical prostatectomy (RP) is safe and could reduce the risk of cancer recurrence and mortality in high-risk patients. According to Mark Garzotto, MD, Associate Professor of Urology and Radiation Medicine at Oregon Health & Sciences...

  • Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma. Paule, Bernard; Andreani, Paola; Bralet, Marie-Pierre; Guettier, Catherine; Adam, René; Castaing, Denis; Azoulay, Daniel // Clinical Medicine Insights: Oncology;2010, Issue 4, p121 

    Background: There is no standard adjuvant chemotherapy to prevent recurrent cholangiocarcinoma (CCA), a rare cancer with poor prognosis. We assessed the efficacy and safety of GEMOX on intrahepatic and hilar CCA with high-risk factors after curative surgery. Patients and Methods: Twenty two...

  • Evaluating the breast screening programme: the need for surgical audit. Kee, F.; Gorman, D.; Odling-Smee, W. // Journal of the Royal Society of Medicine;Feb1993, Vol. 86 Issue 2, p79 

    It is to be anticipated that a reduction in population mortality attributable to mammographic screening would be heralded by an increasing proportion of breast cancer cases diagnosed at earlier stages and by an improvement in case fatality. Few cancer registers routinely produce incidence or...

  • ANAL CANCER. Jones, D.J.; James, R.D. // BMJ: British Medical Journal (International Edition);7/18/92, Vol. 305 Issue 6846, p169 

    Examines the etiology of anal cancer. Appreciable changes in the treatment patterns of anal cancer; Effectiveness of radiotherapy and chemotherapy in improving the survival rate of patients with anal cancer; Pathology of anal cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics